Carl Zeiss Meditec’s re-rating journey should continue further
21/02/24 -"Despite our near-term estimates being slightly moderated due to the destocking of consumables and anticipated impact from volume-based procurement headwinds, our target price resets higher by c.4%, ..."
Pages
61
Language
English
Published on
21/02/24
You may also be interested by these reports :
19/03/26
Bastide’s H1 results delivered underlying indicators on track towards FY targets, with a net profit from discontinued activities, primarily the ...
19/03/26
MedTechs remain a disaster story – held back by a series of never-ending headwinds, like supply chain, interest rates, slowing China, tariffs etc., ...
18/03/26
We have revised our earnings estimates downward due to ongoing business weaknesses and persistent macroeconomic challenges, which continue to weigh ...
18/03/26
While medium-to-long-term targets appear credible – which also reflect in the upside on fundamental valuation metrics (i.e. DCF and NAV), the ...